Tracking Mood: The Effects of Daily Mood Tracking VAS on Alcohol Consumption in Adult Heavy Drinkers
Launched by ILONA MYLLYNIEMI · May 13, 2024
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial, called "Tracking Mood," is studying how keeping track of one's mood might affect how much alcohol people drink. Specifically, it's looking at adults in the UK who drink heavily—more than 20 units of alcohol per week. Participants in the study will be divided into two groups. One group will track their mood every day using a simple scale, while the other group will just report how much time they spend online. The researchers believe that by regularly tracking moods, participants may be able to reduce their alcohol consumption, which could help improve their overall health.
To be eligible for this study, participants need to be over 18 years old, speak fluent English, and drink more than 20 units of alcohol each week. They should also be located in the UK and have a good track record of completing previous studies on the Prolific platform. However, individuals with ongoing mental health conditions are not eligible to participate. The study will take place entirely online, making it convenient for those who qualify.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Speaking fluent English
- • being over 18 years of age
- • High completion rates of previous studies on the Prolific platform
- • Being located in the United Kingdom
- • Consuming over 20 UK units of alcohol per week
- Exclusion Criteria:
- • Having an ongoing mental health condition
About Ilona Myllyniemi
Ilona Myllyniemi is a dedicated clinical trial sponsor committed to advancing medical research and improving patient outcomes through innovative studies. With a focus on rigorous scientific methodology and ethical standards, Myllyniemi oversees a diverse portfolio of clinical trials that span various therapeutic areas. Her expertise in trial design, regulatory compliance, and stakeholder engagement ensures that each study is conducted with the highest level of integrity and efficacy. By fostering collaboration among researchers, healthcare professionals, and participants, Ilona Myllyniemi plays a pivotal role in driving the development of new treatment options and contributing to the advancement of medical science.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Valerie Voon, PhD, MD
Study Director
University of Cambridge
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported